Reducing amyloid buildup: new enzyme target could revolutionize Alzheimer’s treatment
An enzyme that received little scientific attention turns out to play a major role in amyloid accumulation in the brain.
The protein in question is called IDOL. Research shows it reduces the number of LDL receptors on neurons. These receptors normally help clear amyloid (a protein that accumulates in Alzheimer’s disease) from the brain. Fewer receptors mean less clearance capacity and more buildup.
What caught the researchers’ attention: neurons without IDOL processed amyloid faster, maintained more active connections with neighboring cells, and showed fewer signs of cellular stress. Effects were measurable across multiple brain regions. This was not a marginal shift but a substantial difference in pathology.
Beyond slowing plaques
Most existing Alzheimer’s drugs aim to slow amyloid accumulation, with mixed results. The IDOL finding points to a different route. Instead of blocking production, removing IDOL appears to strengthen clearance through existing biological channels.
According to the researchers, this opens the possibility of treatments that actively help protect the brain from further decline, rather than merely slowing progression. All results so far come from animal models. Still, the combination of reduced plaques and improved cell communication within the same model is an uncommon convergence that warrants further investigation.
What remains to be shown
The next step is understanding how IDOL is regulated and whether inhibiting it in humans can be achieved safely and effectively. Genes that control LDL receptors are also active in other organs, so targeted inhibition without side effects will require precision. That said, identifying an enzyme with such a direct influence on amyloid accumulation is a meaningful addition to the field.